Albumin and plasma exchange for frailty
Treatments studied
This study tests whether giving a protein called albumin along with a blood filtering treatment (plasma exchange) can help improve strength and daily function in older adults who feel weak or frail. It aims to see if this combination can reduce frailty and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You should be able to think clearly and communicate with the study team.
- You need to have some signs of frailty (like feeling tired, losing weight, or walking slower).
- You cannot be allergic to albumin or other blood products.
- You must not have severe heart, liver, or kidney problems.
- You cannot be taking certain blood thinners called direct oral anticoagulants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests whether transfusions of donated plasma can improve frailty and immune function in older adults. It mainly checks safety first, and also looks for signs that the immune system and overall strength may improve.
This study tests an investigational treatment made from special cells (called mesenchymal stromal cells) that might help reduce frailty in older adults. The treatment is given through an IV and aims to improve strength and overall function.
This early study (Phase 1) tests whether a lab-made stem cell product given through an IV is safe in people with “aging frailty.” It looks mainly at side effects and safety while also exploring whether the treatment can be given safely.
This trial tests whether a treatment called plasma exchange (which removes harmful substances from your blood and replaces them with healthy plasma) can help improve the function of other organs, like the kidneys or lungs, in people with advanced liver failure. It aims to find out if this treatment helps you recover better and to identify markers that show if the treatment is working.
This trial tests if giving a medicine called albumin through a vein can help prevent kidney function from getting worse in people hospitalized with worsening heart failure and liver problems. It may be an option if other treatments haven't worked.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
Hear when a new Frailty trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.